Marker Therapeutics Says 'Strategic Prioritization of Clinical Programs With Focus on MT-601 in Patients With Lymphoma'
Marker Therapeutics 表示 “以淋巴瘤患者的 MT-601 为重点的临床项目的战略优先顺序”
Marker Therapeutics Says 'Strategic Prioritization of Clinical Programs With Focus on MT-601 in Patients With Lymphoma'
Marker Therapeutics 表示 “以淋巴瘤患者的 MT-601 为重点的临床项目的战略优先顺序”
使用浏览器的分享功能,分享给你的好友吧